Cosmo Pharmaceuticals N.V.

  • ISIN: NL0011832936
  • Land: Irland

Nachricht vom 10.05.2021 | 07:00

Cosmo Pharmaceuticals announces a change in its board of directors

Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous

10-May-2021 / 06:00 GMT/BST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


*    retirement of Dr. Hans Christoph Tanner as non-executive director
*    proposal for the appointment of Mr. David Maris as new non-executive board member

Dublin, Ireland - 10 May 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced the resignation, due to his retirement, of Dr. Hans Christoph Tanner as a non-executive board member and the proposal for the appointment of Mr. David Maris as a new non-executive board member, both to take effect from the next AGM on the 28th of May. 

Dr. Tanner, who organized the only private financing round of Cosmo in 2005 and then joined the company as CFO to take it public on SIX in 2007, has been a board member since 2007 and has already retired from his executive positions in February 2020. Dr. Tanner said: 'Cosmo is embarking on a series of new developments that need undivided attention and some fresh input. Therefore, I have decided to retire from my non-executive board position. My time at Cosmo has been thrilling and I wish the company every success for the future'.

Mauro Ajani, Chairman of Cosmo, said: 'I am thankful to Chris for his continued and relentless support of the years. He has been a key factor in the shaping of the company and I am very grateful for that'.

It is proposed to replace Dr. Tanner as a non-executive director with Mr. Maris at the next AGM set for May 28, 2021.

Mr. Maris is a private investor with Phalanx Investment Partners, LLC, an investment advisor, since January 2020, and a member of the board of directors of Amphastar Pharmaceuticals (NASDAQ: AMPH). He also serves as a member of the American Finance Association and National Association of Corporate Directors. Mr. Maris has been a managing director and equity research analyst at Wells Fargo Securities, LLC, an investment bank, from December 2015 up to December 2019. Before serving at Wells Fargo Securities, LLC, Mr. Maris served as a managing director and equity research analyst at Bank of Montreal, an investment bank, in the period from January 2013 to December 2015. Prior to serving Bank of Montreal and Wells Fargo Securities, LLC, he served as a healthcare industry equity analyst for several other investment banks, including Aros Securities, Bear Stearns, Credit Suisse, Bank of America, and Credit Agricole - CLSA. Mr. Maris is a U.S. national and holds a B.A. from the University of Delaware and an M.B.A. from Vanderbilt University's Owen Graduate School of Management.

About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius(TM) its artificial intelligence device that uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo(R) to Red Hill Biopharma Ltd. for the US and has licensed Relafalk(R) to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Calendar  
Annual General Meeting, Amsterdam May 28, 2021
Half-Year 2021 Report July 30, 2021
Investora Conference, Zurich September 15/16, 2021

Disclaimer
Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.

This press release constitutes neither an offer to sell nor a solicitation to buy securities and it does not constitute a prospectus within the meaning of article 652a and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any similar document. The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.

This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.

This press release does not constitute an "offer of securities to the public" within the meaning of Directive 2003/71/EC of the European Union (the "Prospectus Directive") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.

Contact
Niall Donnelly, CFO & Head of Investor Relations
Cosmo Pharmaceuticals N.V.            
Tel: +353 1 817 03 70
ndonnelly@cosmopharma.com



End of ad hoc announcement

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021